ArticleThoracic cancer2023

Investigation of response of patients with non-small cell lung cancer to docetaxel (plus ramucirumab) therapy in second-line treatment.

Yutaka Takahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.